Aquestive Therapeutics (AQST) Total Liabilities (2017 - 2026)

Aquestive Therapeutics' Total Liabilities history runs 10 years deep, the most recent figure standing at $175.2 million for Q1 2026.

• In Q1 2026, Total Liabilities rose 7.36% year-over-year to $175.2 million; the TTM figure through Mar 2026 stood at $175.2 million (up 7.36% YoY), while the FY2025 annual figure was $194.1 million, up 20.12% from the prior year.
• Total Liabilities was $175.2 million for Q1 2026 at Aquestive Therapeutics, down from $194.1 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $194.1 million in Q4 2025 to a low of $149.7 million in Q1 2022.
• Historically, Total Liabilities has averaged $164.7 million across 5 years, with a median of $163.6 million in 2023.
• The sharpest annual moves came in 2022 and 2023: Total Liabilities jumped 31.61% in 2022, then decreased 6.67% in 2023.
• A 5-year view of Total Liabilities shows it stood at $175.6 million in 2022, then decreased by 6.67% to $163.9 million in 2023, then slipped by 1.42% to $161.6 million in 2024, then gained by 20.12% to $194.1 million in 2025, then retreated by 9.74% to $175.2 million in 2026.
• The last three Total Liabilities figures came in at $175.2 million (Q1 2026), $194.1 million (Q4 2025), and $167.7 million (Q3 2025), per Business Quant data.